-
01:26:39 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

NRXP Stock News

01/05/22 6:48 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI® (aviptadil) in patients with Critical COVID-19 who are at
RHEA-AI
negative
12/29/21 6:48 AM
NYSE : NRXP
covid-19
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients with Critical COVID-19 and respiratory failure who are at immediate
RHEA-AI
neutral
12/14/21 6:48 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients First Patient in Brazil Expected to be Included in US National Institutes of
RHEA-AI
negative
12/06/21 9:07 AM
Nasdaq : NRXP
clinical trial
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
Independent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminently NRx has obtained advice from European Medicines Authority and World Health Organization on phase 2b/3 registration trial protocol More than
RHEA-AI
neutral
11/29/21 6:31 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population Analysis was conducted in response to US Food and Drug Administration (FDA) request for
RHEA-AI
neutral
11/26/21 10:06 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research
Analysis of Blood Samples from Patients who Responded to the BriLife ® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter Delta
RHEA-AI
negative